医学综述
醫學綜述
의학종술
MEDICAL RECAPITULATE
2014年
24期
4547-4548,4557
,共3页
张海龙%张俊英%晋学英%牛敬宪%黎珍娟%张凤兰
張海龍%張俊英%晉學英%牛敬憲%黎珍娟%張鳳蘭
장해룡%장준영%진학영%우경헌%려진연%장봉란
强直性脊柱炎%Th17细胞%调节性T细胞%Th1细胞
彊直性脊柱炎%Th17細胞%調節性T細胞%Th1細胞
강직성척주염%Th17세포%조절성T세포%Th1세포
Ankylosing spondylitis%Th17 cells%Regulatory T cells%Th1 cells
目的:探讨效应CD4+T细胞分泌的Th1细胞、Th17细胞及调节性T细胞( Treg)免疫平衡失调与强直性脊柱炎( AS)患者强直性脊柱炎疾病活动评分( ASDAS)的关系。方法采用流式细胞仪测定60例强直性脊柱炎患者( AS组)及60例健康体检者(对照组)外周血CD4+ Th17、CD4+ Th1及CD4+ CD25+ Treg细胞的比率。应用酶联免疫吸附试验(ELISA)测定白细胞介素(IL)6、IL-8、IL-17、IL-23以及肿瘤细胞坏死因子α( TNFα)等水平。分析不同AS患者Th1、Th17以及Treg细胞免疫失衡情况及与ASDAS相关性。结果 AS组患者CD4+ Th17细胞水平高于对照组,而CD4+ Th1及CD4+CD25+ Treg细胞水平低于对照组,差异有统计学意义(P<0.05)。 AS组IL-6、IL-17、IL-23及TNFα蛋白水平高于对照组(P<0.05)。与病情稳定(ASDAS<1.3)患者、病情中度活动患者(1.3≤ASDAS<2.1)相比,重度患者(ASDAS≥2.1)CD4+ Th17细胞水平、IL-6、IL-17、IL-23及TNFα蛋白水平显著升高(P<0.05),而CD4+ Th1、CD4+CD25+ Treg细胞显著下降(P<0.05)。经Pearson相关分析可知,ASDAS与IL-6(r=0.412,P=0.000), IL-17(r=0.396,P=0.000), IL-23(r=0.384,P=0.000)及TNFα(r=0.318,P=0.004)呈正相关。结论 AS患者中存在Th1细胞、Th17细胞及Treg细胞免疫平衡失调,且与AS患者ASDAS程度具有密切的关系,可为AS临床防治提供指导。
目的:探討效應CD4+T細胞分泌的Th1細胞、Th17細胞及調節性T細胞( Treg)免疫平衡失調與彊直性脊柱炎( AS)患者彊直性脊柱炎疾病活動評分( ASDAS)的關繫。方法採用流式細胞儀測定60例彊直性脊柱炎患者( AS組)及60例健康體檢者(對照組)外週血CD4+ Th17、CD4+ Th1及CD4+ CD25+ Treg細胞的比率。應用酶聯免疫吸附試驗(ELISA)測定白細胞介素(IL)6、IL-8、IL-17、IL-23以及腫瘤細胞壞死因子α( TNFα)等水平。分析不同AS患者Th1、Th17以及Treg細胞免疫失衡情況及與ASDAS相關性。結果 AS組患者CD4+ Th17細胞水平高于對照組,而CD4+ Th1及CD4+CD25+ Treg細胞水平低于對照組,差異有統計學意義(P<0.05)。 AS組IL-6、IL-17、IL-23及TNFα蛋白水平高于對照組(P<0.05)。與病情穩定(ASDAS<1.3)患者、病情中度活動患者(1.3≤ASDAS<2.1)相比,重度患者(ASDAS≥2.1)CD4+ Th17細胞水平、IL-6、IL-17、IL-23及TNFα蛋白水平顯著升高(P<0.05),而CD4+ Th1、CD4+CD25+ Treg細胞顯著下降(P<0.05)。經Pearson相關分析可知,ASDAS與IL-6(r=0.412,P=0.000), IL-17(r=0.396,P=0.000), IL-23(r=0.384,P=0.000)及TNFα(r=0.318,P=0.004)呈正相關。結論 AS患者中存在Th1細胞、Th17細胞及Treg細胞免疫平衡失調,且與AS患者ASDAS程度具有密切的關繫,可為AS臨床防治提供指導。
목적:탐토효응CD4+T세포분비적Th1세포、Th17세포급조절성T세포( Treg)면역평형실조여강직성척주염( AS)환자강직성척주염질병활동평분( ASDAS)적관계。방법채용류식세포의측정60례강직성척주염환자( AS조)급60례건강체검자(대조조)외주혈CD4+ Th17、CD4+ Th1급CD4+ CD25+ Treg세포적비솔。응용매련면역흡부시험(ELISA)측정백세포개소(IL)6、IL-8、IL-17、IL-23이급종류세포배사인자α( TNFα)등수평。분석불동AS환자Th1、Th17이급Treg세포면역실형정황급여ASDAS상관성。결과 AS조환자CD4+ Th17세포수평고우대조조,이CD4+ Th1급CD4+CD25+ Treg세포수평저우대조조,차이유통계학의의(P<0.05)。 AS조IL-6、IL-17、IL-23급TNFα단백수평고우대조조(P<0.05)。여병정은정(ASDAS<1.3)환자、병정중도활동환자(1.3≤ASDAS<2.1)상비,중도환자(ASDAS≥2.1)CD4+ Th17세포수평、IL-6、IL-17、IL-23급TNFα단백수평현저승고(P<0.05),이CD4+ Th1、CD4+CD25+ Treg세포현저하강(P<0.05)。경Pearson상관분석가지,ASDAS여IL-6(r=0.412,P=0.000), IL-17(r=0.396,P=0.000), IL-23(r=0.384,P=0.000)급TNFα(r=0.318,P=0.004)정정상관。결론 AS환자중존재Th1세포、Th17세포급Treg세포면역평형실조,차여AS환자ASDAS정도구유밀절적관계,가위AS림상방치제공지도。
Objective To investigate the relationship of immune imbalance with Ankylosing Spondylitis ( AS) patients with disease activity ( ASDAS) of Th17 cells,Th1 cell,regulatory T cells ( Treg) . Methods The cell tstions of blood CD4 + Th17, CD4 + Th1 and CD4 + CD25 + Treg of AS patients(n=60)and control group(n=60)were detected with flow cytometry. The levels of interleukin -6, IL-8, IL-17, IL-23, (IL-6, IL-8, IL-17, IL-23) and tumor necrosis factorα (TNFα) were Measured with ELISA. The relation-ship of immune imbalance of Th1,Th17 and Treg cell between ASDAS were analyzed. Results The levels of CD4 + Th1 and CD4 + CD25 + Treg cell of AS group were lower than control group(P<0. 05). The lev-els of IL-6,IL-17, IL-23 and TNFαof AS group were higher than control group(P<0. 05). The levels of CD4 +Th17,IL-6,IL-17,IL-23 and TNFαof severe group (ASDAS≥2. 1) were higher than stable disease ( ASDAS <1. 3) group and moderate disease activity group (1. 3≤ASDAS<2. 1) . and the levels of CD4 +Th1, CD4 + CD25 + Treg cells of severe group (ASDAS≥2. 1) were lower than stable disease (ASDAS <1. 3) group and moderate disease activity group (1. 3≤ASDAS<2. 1),the differences were all statistically significant (P<0. 05). By Pearson correlation analysis shows, IL-6 (r = 0. 412, P = 0. 000), IL-17 (r= 0.396, P = 0.000), IL-23 (r = 0.384, P = 0.000) and TNFα(r = 0.318, P = 0.004) were positively correlated with ASDAS. Conclusion AS presence of Th1 cells in patients , Th17 cells and Treg cell immune imbalance, and has a close relationship with the degree of ASDAS AS patients, can provide guidance for the prevention and treatment of AS.